Skip to main content

turmetabart adizutecan

Generic: Turmetabart Adizutecan

turmetabart adizutecan: 2 clinical trials tracked.

turmetabart adizutecan evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about turmetabart adizutecan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trials (2)

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)

NCT07365241·Phase 3·ABBV
Recruiting

Primary endpoint: Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR)

InterventionalRandomizedopen531 targetStarted 2026-07Completion 2030-0950 sites · Austria, France, Germany, Greece…AbbVie

A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT07155174·Phase 2·ABBV
Recruiting

Primary endpoint: Number of Participants with Adverse Events (AE)s

InterventionalRandomizedopen180 targetStarted 2025-11Completion 2031-0950 sites · Belgium, China, Germany, Israel…AbbVie